ArticleThe Journal of international medical research2025
Severe relapse of Evans syndrome in an adult patient with treatment resistance and fatal outcome: A case report.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evans syndrome is an uncommon autoimmune disorder characterized by autoimmune hemolytic anemia and immune thrombocytopenia. It can follow a relapsing course in adults and may be challenging to treat. A woman in her 50s, diagnosed with Evans syndrome 2 years ago and on 10 mg prednisolone once daily, presented with worsening symptoms, lymphadenopathy, and abnormal uterine bleeding. Lymph node biopsies revealed caseating and noncaseating granulomas, and infections and systemic autoimmune diseases were ruled out. She required intensive care unit admission and treatment with high-dose corticosteroids and rituximab. Plasmapheresis was attempted as the last-line therapy; however, it resulted in hemodynamic instability. This case reflects the clinical challenges involved in managing relapsed Evans syndrome in the absence of a clear secondary cause. The presence of granulomatous inflammation raises questions about lesser-known immune features of the disease. The use of plasmapheresis in unstable patients should be approached with caution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.